STOCK TITAN

[SCHEDULE 13G/A] Celcuity Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. have filed Amendment No. 3 to Schedule 13G on Celcuity Inc. (NASDAQ: CELC). As of 30 June 2025 the group beneficially owns 1,633,208 common shares, equal to 4.31 % of the 37,866,358 shares outstanding (per Celcuity’s 15 May 2025 SEC filing). Because the position now stands at or below the 5 % threshold, Item 5 is checked, signalling ownership of “5 percent or less of a class.”

The shares are held directly by the Cayman-based Perceptive Life Sciences Master Fund. Voting and dispositive power over the full block is shared among the Master Fund, Perceptive Advisors (investment manager) and Mr. Edelman (managing member). None of the reporting persons holds sole voting or dispositive power. The filing states the securities were not acquired to influence control of the issuer. Signatures are dated 4 Aug 2025.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Perceptive still owns 1.63 M CELC shares but dip below 5 % trims visibility—mildly negative signal.

Perceptive Advisors is a marquee biotech investor; its presence lends credibility to Celcuity. However, the amended 13G shows ownership has fallen to 4.31 %, crossing under the 5 % reporting line. While the firm remains a top‐10 holder, reduced exposure can imply profit-taking or portfolio rebalancing ahead of catalysts. The drop also lifts Perceptive’s obligation to file future 13D/G updates unless it again tops 5 %, lowering transparency for public investors. Impact: modestly negative for sentiment but not thesis-changing.

TL;DR: Routine compliance filing—no control intent disclosed; governance impact neutral.

This Schedule 13G/A confirms that Perceptive, Edelman and the Master Fund act as passive investors. Shared voting/dispositive power across entities is standard for fund structures and no concerted control activity is indicated. Certification under Item 10 reinforces passive intent. From a governance standpoint the disclosure is ordinary and poses no new risk factors for minority shareholders.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/04/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:08/04/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/04/2025
Celcuity Inc

NASDAQ:CELC

CELC Rankings

CELC Latest News

CELC Latest SEC Filings

CELC Stock Data

3.35B
34.64M
12.04%
84.06%
13.25%
Biotechnology
Services-medical Laboratories
Link
United States
MINNEAPOLIS